Forbion is a global venture capital firm founded in 2004, managing approximately €7.5 billion across 13 funds with over 140 investments made. The firm operates two core investment strategies: Human Health and Planetary Health. Within Human Health, Forbion runs three sub-strategies—Ventures (pre-clinical and early clinical companies), Growth (clinical-stage private growth capital, crossovers, and public investments), and Formation (pre-creation/pre-seed through a joint venture with BioGeneration Ventures). The Planetary Health strategy focuses on BioEconomy investments in companies leveraging biotechnology across food, agriculture, materials, and environmental technologies. Forbion has offices in Naarden (Netherlands), Munich (Germany), and Boston (US), with a team of over 50 professionals of diverse nationalities. The firm integrates ESG principles across its portfolio, focusing on patient impact, societal benefits, and sustainability. Recent investments include OMass Therapeutics ($310M Series C), Calluna Pharma, Amphista Therapeutics, Azafaros, VectorY, and Genomines.

Profile auto-generated from public sources — details unverified.